"DARRT‐2 has already started, in the sense that the planning process is well underway. The NOX team is working very hard to fulfill all administrative and clinical study requirements to be able to start enrolling the first patient as soon as possible. We have set a target of recruiting the first patient early in the New Year. What will it mean to me as a shareholder if DARRT‐2 is successful?
It will mean that Veyonda® becomes a realistic commercial prospect in the search for a new last‐line therapy for end‐stage prostate cancer, a market the Company assesses as being a multi‐billion dollar one
It will mean the Company (and the market) being able to ascribe a dollar value to Veyonda® based on Phase 2 data
It will mean having the clinical data to enter into discussions with potential industry partners"
This is not the first time they have shifted focus and missed promised milestones but this one is huge........ Phase I again. LOL You have my sympathies RBX. Not even a note to explain to investors this huge change of direction......again.
- Forums
- ASX - By Stock
- NOX
- DARRT-2
DARRT-2, page-2
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.0¢ |
Change
0.005(4.76%) |
Mkt cap ! $32.14M |
Open | High | Low | Value | Volume |
11.5¢ | 11.5¢ | 11.0¢ | $18.94K | 171.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 50000 | 11.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
12.5¢ | 66800 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 100532 | 0.105 |
6 | 393641 | 0.100 |
1 | 53000 | 0.096 |
1 | 20000 | 0.095 |
1 | 100000 | 0.092 |
Price($) | Vol. | No. |
---|---|---|
0.125 | 66800 | 1 |
0.130 | 131463 | 3 |
0.135 | 30000 | 1 |
0.140 | 39486 | 2 |
0.145 | 100000 | 1 |
Last trade - 14.48pm 08/11/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online